M. Mauer

VP3-2022: Pembrolizumab (pembro) versus placebo for early-stage non-small cell lung cancer (NSCLC) following complete resection and adjuvant chemotherapy (chemo) when indicated: Randomized, triple-blind, phase III EORTC-1416-LCG/ETOP 8-15 – PEARLS/KEYNOTE-091 study

L. Paz-Ares, E O’Brien, M. Mauer et al. · Annals of Oncology · 2022 · 71 citations

Medicine, Clinical Trials, Adjuvant Chemotherapy +9

Concurrent coronary and carotid artery surgery: factors influencing perioperative outcome and long-term results†

Philippe Kolh, Laetitia Comté, Vincent Tchana‐Sato et al. · European Heart Journal · 2005 · 51 citations · Full text

Neoadjuvant chemotherapy versus surgery alone for locally advanced adenocarcinoma of the stomach and cardia: Randomized EORTC phase III trial #40954

C Schuhmacher, P. Schlag, Florian Lordick et al. · Journal of Clinical Oncology · 2009 · 29 citations

Surgical Oncology, Gastrointestinal Oncology, Median Survival +11

Adjuvant immunotherapy in patients with resected gastric and oesophagogastric junction cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1): European Organisation of Research and Treatment of Cancer (EORTC) 1707 VESTIGE study

Florian Lordick, M. Mauer, Gertraud Stocker et al. · Annals of Oncology · 2024 · 29 citations · Full text

PG 6.2 Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer: disease free survival results at interim analysis

Hans‐Joachim Schmoll, Karin Haustermans, Timothy Price et al. · European Journal of Cancer · 2014 · 20 citations

Interim Analysis, Postoperative Chemotherapy, Surgical Oncology +8